Discovery of penicillic acid as a chemical probe against tau aggregation in Alzheimer's disease

被引：0

作者：

Shyong, Jennifer ^{[1
]}

Wang, Jinliang ^{[1
]}

Huynh, Quoc-Dung Tran ^{[4
]}

Fayzullina, Marina ^{[1
]}

Yuan, Bo ^{[1
]}

Lee, Ching-Kuo ^{[3
,4
]}

Minehan, Thomas ^{[5
]}

Seidler, Paul M. ^{[1
]}

Wang, Clay C. C. ^{[1
,2
]}

机构：

[1] Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles,CA,90089, United States

[2] Department of Chemistry, University of Southern California, Dornsife College of Letters, Arts and Sciences, Los Angeles,CA,90089, United States

[3] School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei,11031, Taiwan

[4] PhD Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei,11031, Taiwan

[5] Department of Chemistry and Biochemistry, California State University, Northridge, Northridge,CA,91330, United States

来源：

Chemical Science | 2024年 / 15卷 / 48期

关键词：

Alzheimer's Disease (AD) is a neurodegenerative disorder proven to be caused by the aggregation of protein tau into fibrils; resulting in neuronal death. The irreparable neuronal damage leads to irreversible symptoms with no cure; therefore; disaggregation of these tau fibrils could be targeted as a therapeutic approach to AD. Here we have developed a fungal natural product library to screen for secondary metabolites that have bioactive potential towards AD tau. Our initial screenings indicate that penicillic acid demonstrates anti-aggregation activity towards tau; while further in vitro experiments reveal that penicillic acid directly inhibits tau by disaggregating fibrils. Although penicillic acid possesses blood-brain barrier penetrability properties that are computationally predicted to be favorable; it is presumed to contain some mutagenic effects as well. To address this; we used the backbone of penicillic acid as a chemical probe to discover similar compounds that can inhibit AD tau aggregation with limited mutagenicity. This work suggests the potential of discovering chemical probes through natural product screening for small-molecule drug discovery of tauopathies. © 2024 The Royal Society of Chemistry;

D O I：

10.1039/d4sc05469e

中图分类号：

学科分类号：

摘要：

引用

页码：20467 / 20477

共 50 条

[41] Tau, tangles, and Alzheimer's disease
Binder, LI
Guillozet-Bongaarts, AL
Garcia-Sierra, F
Berry, RW
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3): : 216 - 223
[42] Tau phosphorylation in Alzheimer's disease
Hanger, D
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S100 - S100
[43] The role of tau in Alzheimer's disease
Trojanowski, JQ
Lee, VMY
MEDICAL CLINICS OF NORTH AMERICA, 2002, 86 (03) : 615 - +
[44] Dendritic Tau in Alzheimer's Disease
Ittner, Arne
Ittner, Lars M.
NEURON, 2018, 99 (01) : 13 - 27
[45] Aluminium, tau and Alzheimer's disease
Exley, Christopher
JOURNAL OF ALZHEIMERS DISEASE, 2007, 12 (04) : 313 - 315
[46] The complexity of tau in Alzheimer's disease
Naseri, Nima N.
Wang, Hong
Guo, Jennifer
Sharma, Manu
Luo, Wenjie
NEUROSCIENCE LETTERS, 2019, 705 : 183 - 194
[47] Tau immunotherapies for Alzheimer's disease
Hoskin, Justin L.
Sabbagh, Marwan Noel
Al-Hasan, Yazan
Decourt, Boris
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (06) : 545 - 554
[48] Tau protein and Alzheimer's disease
Kosik, K. S.
CURRENT OPINION IN CELL BIOLOGY, 1990, 2 (01) : 101 - 104
[49] Tau, Neurodegeneration and Alzheimer's Disease
Alonso, Alejandra del Carmen
CURRENT ALZHEIMER RESEARCH, 2010, 7 (08) : 653 - 655
[50] Tau Protein in Alzheimer's Disease
Maccioni, Ricardo B.
CURRENT ALZHEIMER RESEARCH, 2011, 8 (06) : 607 - 607

← 1 2 3 4 5 →